The Latin America, Middle East and Africa Emphysema Treatment Market would witness market growth of 8.4% CAGR during the forecast period (2022-2028).
Bronchodilators are medications that relax the muscles surrounding your airways and help you breathe easier. This allows the patients because it opens their airways, which makes it simpler for them to live. The vast majority of bronchodilators are administered through inhalers. When the patient's condition is more severe, the inhaler could additionally include steroids to help decrease inflammation. Vaccines against influenza and pneumococcal pneumonia, given that patients with emphysema have a greater likelihood of experiencing catastrophic complications as a result of these infections. Antibiotic treatment may be helpful if the patient develops a bacterial or viral lung infection.
When trying to diagnose emphysema, an x-ray of the chest is often taken into consideration. On the other hand, a person who has emphysema may have chest X-rays that show average results. The cross-sectional views of internal organs that are produced by computerized tomography (CT) scans are created by combining X-ray pictures that have been obtained from a variety of orientations. Therefore, emphysema may be detected and diagnosed with CT scans in some instances.
For the United Arab Emirates (UAE) healthcare business to promote itself as a leading supplier of healthcare for both its inhabitants and as a destination for medical tourism, a significant number of infrastructural and operational modifications have been implemented. In the continuing pandemic caused by COVID-19, these significant breakthroughs have recently received recognition and appreciation. As a result of the ongoing investments that are being made to enhance the sectors hard and soft infrastructure, the United Arab Emirates (UAE) has been recognized as one of the safest locations in the world in the fight against the COVID-19 pandemic.
This recognition comes as a direct result of the efforts being made by the UAE to combat the pandemic. Because of the widespread distribution of COVID-19 in the area, an increasing number of individuals are exhibiting symptoms comparable to those of COPD. As a consequence, there has been an increase in the demand for bronchodilators and steroids. As a direct consequence, the market for emphysema treatment in the LAMEA area would expand.
The Brazil market dominated the LAMEA Emphysema Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $93.9 million by 2028. The Argentina market is anticipated to grow at a CAGR of 8.9% during (2022 - 2028). Additionally, The UAE market would exhibit a CAGR of 8.1% during (2022 - 2028).
Based on Medication Type, the market is segmented into Bronchodilators, Steroids, and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Online Providers. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Novartis AG, Viatris, Inc., Orion Corporation, GlaxoSmithKline PLC, Pfizer, Inc., Hikma Pharmaceuticals PLC, Boehringer Ingelheim International GmbH and Verona Pharma Plc.
Bronchodilators are medications that relax the muscles surrounding your airways and help you breathe easier. This allows the patients because it opens their airways, which makes it simpler for them to live. The vast majority of bronchodilators are administered through inhalers. When the patient's condition is more severe, the inhaler could additionally include steroids to help decrease inflammation. Vaccines against influenza and pneumococcal pneumonia, given that patients with emphysema have a greater likelihood of experiencing catastrophic complications as a result of these infections. Antibiotic treatment may be helpful if the patient develops a bacterial or viral lung infection.
When trying to diagnose emphysema, an x-ray of the chest is often taken into consideration. On the other hand, a person who has emphysema may have chest X-rays that show average results. The cross-sectional views of internal organs that are produced by computerized tomography (CT) scans are created by combining X-ray pictures that have been obtained from a variety of orientations. Therefore, emphysema may be detected and diagnosed with CT scans in some instances.
For the United Arab Emirates (UAE) healthcare business to promote itself as a leading supplier of healthcare for both its inhabitants and as a destination for medical tourism, a significant number of infrastructural and operational modifications have been implemented. In the continuing pandemic caused by COVID-19, these significant breakthroughs have recently received recognition and appreciation. As a result of the ongoing investments that are being made to enhance the sectors hard and soft infrastructure, the United Arab Emirates (UAE) has been recognized as one of the safest locations in the world in the fight against the COVID-19 pandemic.
This recognition comes as a direct result of the efforts being made by the UAE to combat the pandemic. Because of the widespread distribution of COVID-19 in the area, an increasing number of individuals are exhibiting symptoms comparable to those of COPD. As a consequence, there has been an increase in the demand for bronchodilators and steroids. As a direct consequence, the market for emphysema treatment in the LAMEA area would expand.
The Brazil market dominated the LAMEA Emphysema Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $93.9 million by 2028. The Argentina market is anticipated to grow at a CAGR of 8.9% during (2022 - 2028). Additionally, The UAE market would exhibit a CAGR of 8.1% during (2022 - 2028).
Based on Medication Type, the market is segmented into Bronchodilators, Steroids, and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Online Providers. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Novartis AG, Viatris, Inc., Orion Corporation, GlaxoSmithKline PLC, Pfizer, Inc., Hikma Pharmaceuticals PLC, Boehringer Ingelheim International GmbH and Verona Pharma Plc.
Scope of the Study
Market Segments Covered in the Report:
By Medication Type
- Bronchodilators
- Steroids
- Others
By Distribution Channel
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- AstraZeneca PLC
- Teva Pharmaceuticals Industries Ltd
- Novartis AG
- Viatris, Inc
- Orion Corporation
- GlaxoSmithKline PLC
- Pfizer, Inc
- Hikma Pharmaceuticals PLC
- Boehringer Ingelheim International GmbH
- Verona Pharma Plc
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Emphysema Treatment Market, by Medication Type
1.4.2 LAMEA Emphysema Treatment Market, by Distribution Channel
1.4.3 LAMEA Emphysema Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Emphysema Treatment Market
Chapter 4. LAMEA Emphysema Treatment Market by Medication Type
4.1 LAMEA Bronchodilators Market by Country
4.2 LAMEA Steroids Market by Country
4.3 LAMEA Others Market by Country
Chapter 5. LAMEA Emphysema Treatment Market by Distribution Channel
5.1 LAMEA Drug Stores & Retail Pharmacies Market by Country
5.2 LAMEA Hospital Pharmacies Market by Country
5.3 LAMEA Online Providers Market by Country
Chapter 6. LAMEA Emphysema Treatment Market by Country
6.1 Brazil Emphysema Treatment Market
6.1.1 Brazil Emphysema Treatment Market by Medication Type
6.1.2 Brazil Emphysema Treatment Market by Distribution Channel
6.2 Argentina Emphysema Treatment Market
6.2.1 Argentina Emphysema Treatment Market by Medication Type
6.2.2 Argentina Emphysema Treatment Market by Distribution Channel
6.3 UAE Emphysema Treatment Market
6.3.1 UAE Emphysema Treatment Market by Medication Type
6.3.2 UAE Emphysema Treatment Market by Distribution Channel
6.4 Saudi Arabia Emphysema Treatment Market
6.4.1 Saudi Arabia Emphysema Treatment Market by Medication Type
6.4.2 Saudi Arabia Emphysema Treatment Market by Distribution Channel
6.5 South Africa Emphysema Treatment Market
6.5.1 South Africa Emphysema Treatment Market by Medication Type
6.5.2 South Africa Emphysema Treatment Market by Distribution Channel
6.6 Nigeria Emphysema Treatment Market
6.6.1 Nigeria Emphysema Treatment Market by Medication Type
6.6.2 Nigeria Emphysema Treatment Market by Distribution Channel
6.7 Rest of LAMEA Emphysema Treatment Market
6.7.1 Rest of LAMEA Emphysema Treatment Market by Medication Type
6.7.2 Rest of LAMEA Emphysema Treatment Market by Distribution Channel
Chapter 7. Company Profiles
7.1 AstraZeneca PLC
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Partnerships, Collaborations, and Agreements:
7.1.5.2 Approvals and Trials:
7.2 Teva Pharmaceutical Industries Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Product Launches and Product Expansions:
7.3 Novartis AG
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Approvals and Trials:
7.4 Viatris, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Approvals and Trials:
7.5 Orion Corporation
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.6 GlaxoSmithKline PLC
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Product Launches and Product Expansions:
7.6.5.2 Approvals and Trials:
7.7 Pfizer, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional & Segmental Analysis
7.7.4 Research & Development Expense
7.8 Hikma Pharmaceuticals PLC
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expenses
7.9 Boehringer Ingelheim International Gmbh
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional & Segmental Analysis
7.9.4 Research & Development Expenses
7.10. Verona Pharma Plc
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Research & Development Expenses
Companies Mentioned
- AstraZeneca PLC
- Teva Pharmaceuticals Industries Ltd.
- Novartis AG
- Viatris, Inc.
- Orion Corporation
- GlaxoSmithKline PLC
- Pfizer, Inc.
- Hikma Pharmaceuticals PLC
- Boehringer Ingelheim International GmbH
- Verona Pharma Plc
Methodology
LOADING...
